Microvast Holdings announces departure of chief financial officer
TEL AVIV - SciSparc Ltd. (NASDAQ:SPRC), a clinical-stage pharmaceutical company with a market capitalization of $3.45 million, announced today a new Japanese divisional patent for a pharmaceutical combination that could potentially improve pain and fever treatment. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 5.36x and holds more cash than debt on its balance sheet. The patent application details a combination of paracetamol and palmitoylethanolamide (PEA), which may offer enhanced relief with lower doses and reduced side effects compared to standard paracetamol therapy.
The innovation lies in the synergy between paracetamol, commonly used for pain and fever, and PEA, a substance that augments the body’s endocannabinoid system. This combination could potentially lower the required dose of paracetamol, thereby diminishing the risk of side effects such as liver damage, while providing better outcomes for various types of pain and fever.
SciSparc’s CEO, Oz Adler, stated that this patent represents a significant advancement in pain management. The development could potentially provide a safer option for patients globally, given the widespread use of paracetamol. InvestingPro data shows analysts expect revenue growth of 17.3% this year, though the company is currently experiencing rapid cash burn. Get access to 10+ additional exclusive ProTips and comprehensive financial metrics with InvestingPro.
SciSparc focuses on cannabinoid-based pharmaceuticals and is involved in several drug development programs targeting conditions such as Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. The company also holds a controlling interest in a subsidiary selling hemp seed oil products on Amazon.com.
The press release also contains forward-looking statements regarding the potential benefits of the paracetamol and PEA combination. However, these statements are subject to risks and uncertainties, and actual results may differ from current expectations. The company’s latest financial and risk details are available in its Annual Report on Form 20-F filed on April 24, 2025, with the U.S. Securities and Exchange Commission. Investors should note that SciSparc’s next earnings report is scheduled for May 30, 2025, and InvestingPro’s Fair Value analysis suggests the stock is currently undervalued, despite showing a -72.8% return over the past year.
This news article is based on a press release statement from SciSparc Ltd. and does not include any additional analysis or opinion.
In other recent news, SciSparc Ltd. has announced a $2 million loan agreement with AutoMax Motors Ltd. to aid in its business expansion, specifically focusing on the direct import of JAC electric vehicles. This loan follows previous bridge loans totaling $4.25 million. The loan terms include an 8% annual interest rate, with monthly repayments of $50,000 plus interest. AutoMax has the option for early repayment without penalties. Notably, upon completion of a merger agreement between SciSparc and AutoMax, the interest on the loan will be canceled, although the principal amount will still be due. This merger agreement, which was entered into in April 2024, involves SciSparc acquiring 100% of AutoMax, pending shareholder approvals and other customary closing conditions. Additionally, SciSparc has scheduled its Annual General Meeting of Shareholders for June 25, 2025. The meeting will address standard corporate matters, and shareholders on record as of May 27, 2025, will be eligible to participate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.